Success Story

CAR-T startup Vittoria Biotherapeutics launches

Vittoria Biotherapeutics’ seeks to overcome certain current limitations of chimeric antigen receptor (CAR) T-cell therapeutics through the application of its proprietary cell engineering and gene editing technology platform originally developed at Penn by Marco Ruella, MD, co-founder of Vittoria and Assistant Professor of Medicine at the Center for Cellular Immunotherapies at Penn’s Perelman School of Medicine. Dr. Ruella is also scientific director of the lymphoma program at the Hospital of the University of Pennsylvania as well as a Penn hematologist who came to the United States 10 years ago to study under Penn CAR T-cell pioneer Carl June, MD, Richard W. Vague Professor in Immunotherapy and Saar Gill, MD, PhD, Associate Professor of Medicine.

Skip to content